Bashar Issa
Contributor since: 2020
Undervalued Unum Profiting From Macroeconomic Trends, Plus 4.5% Dividend
Icahn Enterprises: 16% Dividend Yield And Market Correction Protection
Sell Alert: Overvalued Sherwin-Williams Facing A Challenging Second Half
Clover Health: 2 Catalysts To Watch In October And November
How I Was Wrong About Illumina
Microsoft Vs. Apple: Strategy, Balance Sheet, And Valuation
Sunrun: A Chalky Business Model In A Growing Market
Plug Power: A Momentum Trade In An Envision Future Without A Competitive Moat
Blackstone Likely To Go Higher Supported By AUM Growth
Intellia's Bold Bet Pays Off, Meriting Its Valuation
Crispr Therapeutics: Lucrative Partnerships And Promising Data Increase Its Appeal
BHP Group - Miner's Dip Offers A Buying Opportunity
Rio Tinto: Market Correction Opens A Buying Opportunity
Clover Shorts Will Likely Burn - Valuation Revisited
bluebird bio - The Good, The Bad And The Ugly
The Ways Microsoft Generates Its Cash
Issuer Direct Proves Its Pricing Power
Bionano Genomics - Not Out Of The Woods Yet
Workiva Came Through Again. Bullish On Revenue Momentum, Successful Strategy
Higher Volatility Ahead As Bionano Reveals What's Its Made Of During Q2 Earnings Call
Icahn Enterprises Likely To Maintain Dividends As Economy Rebounds
Sherwin-Williams: Here Is What We Like (And Dislike)
Oxford Lane Capital - Take Your Money And Run
How I Was Wrong About Clover
Microsoft: Bullish On Gaming, Azure And Office 365
Salesforce: Bullish On Cloud Mission Unity
To Their Disadvantage, Meme Traders Rescue Institutions Holding Exela's Debt
BlackLine: Cleaning Messy Back Offices
Issuer Direct: Neutral On Competing Revenue Dynamics
Donnelley Financial: Bullish On Turnaround Potential
Workiva: Bullish On Growth Potential, Superior Product Offerings
Broadridge Management Turning Aggressive